Top Journalists
>
Leah Kuntz
Email address
l*****@*******.comGet email address
Influence score
30
Location
United States
Languages
  • English
Covering topics
  • Health & Medicine

View more media outlets and journalists by signing up to AI PR

View latest data and reach out all from one place
Sign up to AI PR Toolkit

Recent Articles

psychiatrictimes.com

First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Dist...

First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
psychiatrictimes.com

Before Treating Excessive Sleepiness, Make Sure You Know What You'r...

Before Treating Excessive Sleepiness, Make Sure You Know What You're Treating
psychiatrictimes.com

Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for...

Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
psychiatrictimes.com

New Analyses of HLP003 for the Adjunctive Treatment of MDD

New Analyses of HLP003 for the Adjunctive Treatment of MDD
psychiatrictimes.com

New Real-World Data Supporting Cariprazine for MDD and Bipolar I De...

New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
psychiatrictimes.com

Insights on the New Adult ADHD Guidelines: A Conversation With the ...

Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
psychiatrictimes.com

Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depre...

Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
psychiatrictimes.com

Positive Topline Results From Phase 3 Panorama Study of DT120 ODT i...

Positive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
psychiatrictimes.com

New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybi...

New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
psychiatrictimes.com

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The...

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
psychiatrictimes.com

Presenting Our September 2026 Theme: Depressive Disorders

Presenting Our September 2026 Theme: Depressive Disorders